Monoclonal antibodies constitute important and useful tools in clinical practice and biotechnology for diagnosing and treating infectious, inflammatory, immunological and neoplastic diseases” Cáceres et al (2019).
Abstract:
Monoclonal antibodies constitute important and useful tools in clinical practice and biotechnology for diagnosing and treating infectious, inflammatory, immunological and neoplastic diseases. This article reviews evidence on the different acute adverse effects of monoclonal antibodies, specifically infusion-related reactions (IRRs), and on the measures that should be taken before and during crises. A literature search using key terms relating to IRRs produced by monoclonal antibodies was undertaken to generate a comprehensive narrative review of the information available. Immunomodulatory monoclonal antibodies may produce IRRs and hypersensitivity-related reactions. Strategies to avoid or minimize the appearance of IRRs depend on the monoclonal antibody and type of patient and reaction (pre-medication, slowing infusion rates, infusion interruption or desensitization, etc.). Considering the great number of available monoclonal antibodies in current practice and those which will soon be authorized, it is mandatory to have clear guidelines that can give support to practitioners and nurses to help them respond quickly and safely to the different IRRs related to the use of these therapeutic drugs.
You may also be interested in…
[rp4wp]
[button link=”https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682763/pdf/tcrm-15-965.pdf” color=”default”]Full Text[/button]
[spacer height=”20px”]
Reference:
Cáceres, M.C., Guerrero-Martín, J., Pérez-Civantos, D., Palomo-López, P., Delgado-Mingorance, J.I. and Durán-Gómez, N. (2019) The importance of early identification of infusion-related reactions to monoclonal antibodies. Therapeutics and Clinical Risk Management. August 1st. doi: 10.2147/TCRM.S204909. eCollection 2019.